{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:27:34Z","timestamp":1789644454050,"version":"4.0.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIDA","award":["R01-DA046049"],"award-info":[{"award-number":["R01-DA046049"]}]},{"name":"NIH grant","award":["T32DA023356"],"award-info":[{"award-number":["T32DA023356"]}]},{"name":"NIH grant","award":["T32DA023356-13"],"award-info":[{"award-number":["T32DA023356-13"]}]},{"name":"Institute for Addiction Science pilot award","award":["PG1033682"],"award-info":[{"award-number":["PG1033682"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01075-x","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:02:20Z","timestamp":1724475740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The fentanyl made me feel like I needed more methadone\u201d: changes in the role and use of medication for opioid use disorder (MOUD) due to fentanyl"],"prefix":"10.1186","volume":"21","author":[{"given":"Maria","family":"Bolshakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhi S.","family":"Ganesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse L.","family":"Goldshear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheyenne J.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky N.","family":"Bluthenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"issue":"1","key":"1075_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12954-023-00805-x","volume":"20","author":"R Abadie","year":"2023","unstructured":"Abadie R. \u201cI don\u2019t want to die\u201d: a qualitative study of coping strategies to prevent fentanyl-related overdose deaths among people who inject drugs and its implications for harm reduction policies. Harm Reduct J. 2023;20(1):75. https:\/\/doi.org\/10.1186\/s12954-023-00805-x.","journal-title":"Harm Reduct J"},{"key":"1075_CR2","volume-title":"Provisional drug overdose death counts","author":"FB Ahmad","year":"2022","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. Hyattsville: National Center for Health Statistics; 2022."},{"issue":"1","key":"1075_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ajad.13069","volume":"30","author":"D Antoine","year":"2021","unstructured":"Antoine D, Huhn AS, Strain EC, et al. Method for successfully inducting individuals who use illicit fentanyl onto buprenorphine\/naloxone. Am J Addict. 2021;30(1):83\u20137.","journal-title":"Am J Addict"},{"key":"1075_CR4","unstructured":"Bromley L, Kahan M, Regenstreif L, Srivastava A, Wyman J, Dabam F. Methadone treatment for people who use fentanyl: recommendations. Toronto: META: PHI. 2021;24."},{"key":"1075_CR5","doi-asserted-by":"publisher","first-page":"108832","DOI":"10.1016\/j.jsat.2022.108832","volume":"141","author":"M Buresh","year":"2022","unstructured":"Buresh M, Nahvi S, Steiger S, Weinstein ZM. Adapting methadone inductions to the fentanyl era. J Subst Abuse Treat. 2022;141:108832.","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"1075_CR6","doi-asserted-by":"publisher","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","volume":"6","author":"LC Chambers","year":"2023","unstructured":"Chambers LC, Hallowell BD, Zullo AR, Paiva TJ, Berk J, Gaither R, Wightman RS. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open. 2023;6(9):e2334540\u2013e2334540.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"1075_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.therap.2020.05.007","volume":"75","author":"M Chappuy","year":"2020","unstructured":"Chappuy M, Trojak B, Nubukpo P, Bachellier J, Bendimerad P, Brousse G, Rolland B. Prolonged-release buprenorphine formulations: perspectives for clinical practice. Therapies. 2020;75(5):397\u2013406.","journal-title":"Therapies"},{"issue":"1","key":"1075_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12954-023-00893-9","volume":"20","author":"D Frank","year":"2023","unstructured":"Frank D, Elliott L, Cleland CM, Walters SM, Joudrey PJ, Russell DM, Meyerson BE, Bennett AS. \u201cAs safe as possible\u201d: a qualitative study of opioid withdrawal and risk behavior among people who use illegal opioids. Harm Reduct J. 2023;20(1):158. https:\/\/doi.org\/10.1186\/s12954-023-00893-9.","journal-title":"Harm Reduct J"},{"issue":"12","key":"1075_CR9","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","volume":"118","author":"J Friedman","year":"2023","unstructured":"Friedman J, Shover CL. Charting the fourth wave: Geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010\u20132021. Addiction (Abingdon Engl). 2023;118(12):2477\u201385. https:\/\/doi.org\/10.1111\/add.16318.","journal-title":"Addiction (Abingdon Engl)"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"108447","DOI":"10.1016\/j.jsat.2021.108447","volume":"131","author":"MG Greiner","year":"2021","unstructured":"Greiner MG, Shulman M, Choo TH, Scodes J, Pavlicova M, Campbell AN, Nunes EV. Naturalistic follow-up after a trial of medications for opioid use disorder: medication status, opioid use, and relapse. J Subst Abuse Treat. 2021;131:108447.","journal-title":"J Subst Abuse Treat"},{"key":"1075_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.drugpo.2019.10.004","volume":"74","author":"BH Lambdin","year":"2019","unstructured":"Lambdin BH, Bluthenthal RN, Zibbell JE, Wenger L, Simpson K, Kral AH. Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs. Int J Drug Policy. 2019;74:299\u2013304.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"1075_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jamainternmed.2021.8114","volume":"182","author":"NP Morris","year":"2022","unstructured":"Morris NP. Opioid use disorder treatment in the age of fentanyl. JAMA Intern Med. 2022;182(3):249\u201350.","journal-title":"JAMA Intern Med"},{"key":"1075_CR13","doi-asserted-by":"publisher","first-page":"108849","DOI":"10.1016\/j.jsat.2022.108849","volume":"141","author":"K LaForge","year":"2022","unstructured":"LaForge K, Stack E, Shin S, Pope J, Larsen JE, Leichtling G, Leahy JM, Seaman A, Hoover D, Byers M, Barrie C, Chisholm L, Korthuis PT. Knowledge, attitudes, and behaviors related to the fentanyl-adulterated drug supply among people who use drugs in Oregon. J Subst Abuse Treat. 2022;141:108849. https:\/\/doi.org\/10.1016\/j.jsat.2022.108849.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"1075_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137\u201345. https:\/\/doi.org\/10.7326\/M17-3107.","journal-title":"Ann Intern Med"},{"key":"1075_CR15","unstructured":"Sen. Markey EJ. Senate\u2014health, education, labor, and pensions. S.644\u2014modernizing opioid treatment access act 118th. 2023."},{"key":"1075_CR16","unstructured":"United States Government. Substance abuse and mental health services administration and department of health and human services. Medications for the treatment of opioid use disorder. (89 FR 7528). 2024."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01075-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01075-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T05:05:18Z","timestamp":1724475918000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01075-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01075-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}